Technical Analysis for KRYS - Krystal Biotech, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| See historical KRYS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | -3.48% | |
| 20 DMA Support | Bullish | -3.48% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -3.48% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -3.48% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/06/2019
- Sector: Healthcare
- Industry: Biotechnology
Krystal Biotech, Inc. gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The Company’s products include KB103 and KB104.The Compnay's KB103 is in preclinical development to treat dystrophic epidermolysis bullosa, or DEB, a rare and severe genetic disease. The Compnay's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, dehydration and stunted growth.
Medicine Rare Diseases Gene Therapy Medical Genetics Genetic Genealogy Genodermatoses Herpes Simplex Virus Epidermolysis Bullosa Itchiness
Medicine Rare Diseases Gene Therapy Medical Genetics Genetic Genealogy Genodermatoses Herpes Simplex Virus Epidermolysis Bullosa Itchiness
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more KRYS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 38.95 |
| 52 Week Low | 10.0 |
| Average Volume | 104,884 |
| 200-Day Moving Average | 22.9795 |
| 50-Day Moving Average | 30.233 |
| 20-Day Moving Average | 33.244 |
| 10-Day Moving Average | 33.965 |
| Average True Range | 1.851 |
| ADX | 30.41 |
| +DI | 27.8607 |
| -DI | 20.2367 |
| Chandelier Exit (Long, 3 ATRs ) | 33.397 |
| Chandelier Exit (Short, 3 ATRs ) | 35.343 |
| Upper Bollinger Band | 36.0518 |
| Lower Bollinger Band | 30.4362 |
| Percent B (%b) | 0.31 |
| BandWidth | 16.892071 |
| MACD Line | 0.9023 |
| MACD Signal Line | 1.1361 |
| MACD Histogram | -0.2339 |
| Fundamentals | Value |
|---|---|
| Market Cap | 310.33 Million |
| Num Shares | 9.64 Million |
| EPS | -0.63 |
| Price-to-Earnings (P/E) Ratio | -51.08 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 33.97 | ||||
| Resistance 3 (R3) | 34.11 | 33.65 | 33.67 | ||
| Resistance 2 (R2) | 33.65 | 33.20 | 33.58 | 33.57 | |
| Resistance 1 (R1) | 32.92 | 32.92 | 32.69 | 32.78 | 33.47 |
| Pivot Point | 32.46 | 32.46 | 32.35 | 32.39 | 32.46 |
| Support 1 (S1) | 31.73 | 32.01 | 31.50 | 31.59 | 30.89 |
| Support 2 (S2) | 31.27 | 31.73 | 31.20 | 30.79 | |
| Support 3 (S3) | 30.54 | 31.27 | 30.69 | ||
| Support 4 (S4) | 30.40 |
